Biomarkers Products & Reviews

Biomarker assay kits

The most comprehensive, high-performance protein biomarker panel available for inflammation studies.

Together with our Neuro Exploratory panel, this provides the most comprehensive, high-performance protein biomarker solution available for neurological disease studies.

The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay is a serological, multiplexed microsphere-based assay to measure the presence of IgG antibodies directed against the nucleocapsid protein (N), Receptor-Binding Domain (RBD) of the spike protein, and the S1 subunit of the spike protein (S1) of SARS-CoV-2 in human serum or plasma. The xMAP SARS-CoV-2 Multi-Antigen IgG Assay features: Broad Coverage: Detects IgG antibodies aga…

SARS-CoV-2 Nucleocapsid, clone 502 Monoclonal Antibody (matched pair with clone 504)

SARS-CoV-2 Nucleocapsid, clone 503 Monoclonal Antibody (matched pair with clone 504)

2019-nCoV Nucleocapsid Recombinant Antigen,full length (Ag-6)

COVID-19, MERS & SARS-CoV, Nucleoprotein Antibody, 1057

COVID-19, MERS & SARS-CoV, Nucleoprotein Antibody, 1058

SARS-CoV-2 Nucleocapsid, clone 504 Monoclonal Antibody (matched pair with clone 502 or 503)

SARS-CoV-2 Nucleocapsid, clone 2A1 Monoclonal Antibody (matched pair with clone 2C1)

SARS-CoV-2 Nucleocapsid, clone 2C1 Monoclonal Antibody (matched pair with clone 2A1)

SARS-CoV-2 Nucleocapsid, clone 4D8 Monoclonal Antibody (matched pair with clone 5B7)

SARS-CoV-2 Nucleocapsid, clone 5B7 Monoclonal Antibody (matched pair with clone 4D8)

SARS-CoV-2 Nucleocapsid,clone 7B3 Monoclonal Antibody (matched pair with clone 5D4)

SARS-CoV-2 Nucleoprotein (aa 1-419) Recombinant Antigen, 613

SARS-CoV-2 Spike (RBD, aa 331-524) Recombinant Antigen

SARS-CoV-2 Spike Protein S1 (aa 1-674) Recombinant Antigen

Tissue Solutions is a leading global provider of ethically sourced human tissue samples used in all areas of drug discovery, research and development. ISO 9001:2015 certified and twice winner of the coveted Queens Award for Enterprise, Tissue Solutions offer a single point of access for a wide range of diseased and normal tissues in fresh, frozen, and FFPE formats.

HistologiX is a leading GLP/GCP accredited Contract Research Organisation based in the UK specialising in Histology, Immunohistochemistry (IHC) and Digital Pathology services. HistologiX works with a broad range of clients from big pharma to small and medium biotech companies worldwide. Our team of scientists have in excess of 120 years combined experience and a customer retention rate of 80%. 

HistologiX is a leading GLP/GCP accredited Contract Research Organisation based in the UK specialising in Histology, Immunohistochemistry (IHC) and Digital Pathology services. HistologiX works with a broad range of clients from big pharma to small and medium biotech companies worldwide. Our team of scientists have in excess of 120 years combined experience and a customer retention rate of 80%. 

Reliable in vivo breath sample collection of VOCs and respiratory droplets for biomarker identification and validation. Suitable for use in a range of contexts and diverse applications including early detection, drug development and precision medicine for conditions including respiratory diseases, liver diseases and cancer. Compatible with a range of analytical systems including GC-MS analysis with Breath Biopsy Services.

Combining high resolution accurate mass mass spectrometry and world-leading breath analysis expertise to offer complete breath biomarker discovery and validation solutions. Breath Biopsy Services provide versatile Breath Biopsy sample analysis and reporting driven by GC-Orbitrap technology and supported by a rigorous quality assurance process ensuring reliable, high sensitivity VOC biomarker detection.

Exogenous volatile organic compound probes (EVOC Probes) enable targeted, non-invasive assessment of biological pathways. Probes are safe, easy to administer compounds that interact with characterised metabolic pathways with relevance to key disease areas. Using Breath Biopsy, EVOC Probes can be monitored non-invasively on breath, either alone or in parallel with biomarker discovery studies.

A targeted panel of compounds with established relevance for respiratory diseases enabling high confidence, non-invasive disease detection and monitoring. Each compound is supported by evidence from breath research studies of relevant respiratory diseases and disease processes. The panel is available as an aspect of Breath Biopsy Services and panels for other disease applications are in development.